⠀
• Moderna and Merck’s Phase 3 INTerpath-001 trial of intismeran plus KEYTRUDA met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival.
• The combination showed statistically significant and clinically meaningful improvements versus KEYTRUDA alone in patients with completely resected Stage IIB-IV melanoma.
• The companies plan to present the data at an upcoming international medical meeting and engage regulators on filing submissions.
